Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 215, Issue 1-2, Pages 117-121Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2009.08.011
Keywords
Multiple sclerosis; Interferon-beta; Dendritic cells
Categories
Funding
- Bayer HealthCare Pharmaceuticals
Ask authors/readers for more resources
Multiple sclerosis (MS) has been characterized as a T cell-mediated autoimmune disease. Recent research on the immunopathology of MS has implicated dendritic cells, professional antigen-presenting cells essential for T cell differentiation and proliferation of self-reactive T cells. Interferon-beta therapy effectively reduces relapse rates in MS and can slow the progression of disability in patients with relapsing-remitting MS. The principal mechanism by which interferon-beta drugs exert their effect is unclear; however, it is possible that an interaction with dendritic cells local to the site of injection may be critical. Most subcutaneously administered interferon-beta never leaves the injection site. This article reviews current concepts on the immunopathogenesis of MS and presents the hypothesis that the main effect of interferon-beta in MS is mediated by local effects on dendritic cells at the injection site. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available